EGFR and neoplasm: As an alternative to the 89Zr label, [64Cu]Cu-DOTA-cetuximab has been characterized in preclinical studies showing satisfactory tumor uptake and clear HER1 visualization in a panel of xenografts (A431, TE-8, TE4, UM-SCC-22B, SCC1) [114,115,116].